This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

30/100

✓ Peer-reviewed alzhub usefulness score 30 out of 100. Mild cognitive impairment

Topic: Risk, prevention and care in population studies

Plain-language summary

Though biomarker assessments showed significant Aβ reduction for both anti-amyloid therapies, no direct correlation with clinical outcomes was observed, limiting their use as surrogate endpoints. Safety evaluation focused on amyloid-related imaging abnormalities (ARIAs), a key risk associated with anti-Aβ antibody treatments.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Yanagihara, R. (2025). Clinical evaluation of medicines for patients with mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan. Alzheimer s & Dementia Translational Research & Clinical Interventions. https://doi.org/10.1002/trc2.70100

Vancouver

Yanagihara R. Clinical evaluation of medicines for patients with mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan. Alzheimer s & Dementia Translational Research & Clinical Interventions. 2025. doi:10.1002/trc2.70100. PMID: 40370495.

BibTeX

@article{yanagihara2025-40370495,
  author  = {Yanagihara, Reiko},
  title   = {{Clinical evaluation of medicines for patients with mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan}},
  journal = {Alzheimer s \& Dementia Translational Research \& Clinical Interventions},
  year    = {2025},
  doi     = {10.1002/trc2.70100},
  pmid    = {40370495},
  url     = {https://doi.org/10.1002/trc2.70100}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

How to read this study

Design: our record does not state a study design, so check the methods section of the original before weighing the result.
Size: the record gives no participant count. Look for one in the original before trusting a pattern.
Effect: the record gives no effect size, so the summary above cannot say how large any difference was.

What the evidence grade means here

This page is graded low. alzhub.org assigns the grade automatically from keywords in the abstract, not from reading the paper. Low means the abstract matched neither pattern. It is the default label, and it does not mean the work is poor; many sound lab and imaging papers land here. It can add at most 5 of the 100 points in the study score, and it is a label about design, not a verdict on whether the findings are true.

New to reading papers? Six questions to ask of any Alzheimer’s study · how we score.

Key findings

Though biomarker assessments showed significant Aβ reduction for both anti-amyloid therapies, no direct correlation with clinical outcomes was observed, limiting their use as surrogate endpoints.
Safety evaluation focused on amyloid-related imaging abnormalities (ARIAs), a key risk associated with anti-Aβ antibody treatments.

Why it matters

This clinical evaluation of medicines for mild cognitive impairment and mild dementia due to Alzheimer's disease in Japan found that although anti-amyloid therapies significantly reduced amyloid-beta, this reduction did not directly correlate with clinical outcomes. Safety evaluation focused on amyloid-related imaging abnormalities, a key risk of anti-amyloid antibody treatments.

Study details

Evidence strengthLow

How this study scored 30/100

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 29 of the 96 points we could judge it on, which is 30 out of 100.

Component	Points	Why
Journal tier	7 / 10	Tier 3 — peer-reviewed journal (Alzheimer s & Dementia Translational Research & Clinical Interventions)
Journal's citation record	1 / 4	Alzheimer s & Dementia Translational Research & Clinical Interventions: journal h-index 84 (OpenAlex, 2026-10-29)
Study design	0 / 12	No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence	1 / 5	Rated “low” in our summary
Peer-review validation	10 / 10	Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent	4 / 5	2025 — within 3 year(s) of the newest study here
Sample size	0 / 4	Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported	0 / 3	No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people	0 / 3	Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded	0 / 2	No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited	1 / 7	Cited 1 times (OpenAlex, 2026-10-10)
Citations per year	0 / 5	0.3 citations a year over 3 year(s) since 2025
Impact for its field and year	1 / 6	Cited 0.5× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here	0 / 6	No other study in this library cites it
Still being cited	0 / 4	Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record	— / 4	OpenAlex's profile for last-listed author Reiko Yanagihara holds only 3 work(s), too few to judge a track record — left out of this score
Institution's track record	0 / 3	Pharmaceuticals and Medical Devices Agency: institution h-index 82 (OpenAlex)
Multicenter collaboration	0 / 3	OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete)
Indexed in PubMed	2 / 2	Indexed in PubMed (PMID 40370495)
Free to read	2 / 2	Free to read
Points	29 / 96	Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 29 of the 96 points we could judge it on is 30 out of 100.
Total	30 / 100	—

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Mild cognitive impairment from nearby years

Also tagged “mini-mental”

840 studies in the library carry the topic tag “mini-mental”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 840 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →